https://www.prnewswire.com/news-releases/innovent-announces-nmpa-granted-marketing-approval-for-sulinno-adalimumab-injection-in-china-301123750.html?utm_source=STAT+Newsletters&utm_campaign=6744470c8f-stat_china_COPY_01&utm_medium=email&utm_term=0_8cab1d7961-6744470c8f-149692869

Innovent’s Humira biosimilar approved

China’s National Medical Product Administration has approved Innovent Biologics’s copycat version of Humira, the world’s best-selling drug in 2019.

Also known as adalimumab, AbbVie’s blockbuster therapy has been marketed in China since 2010. The Chinese biotech’s version of Humira, approved by China for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis, will be marketed as Sulinno.

This is Innovent’s third product approved in China, behind its PD-1 drug Tyvyt and Byvasda, a biosimilar version of Roche’s Avastin.

Sulinno is also the third Humira biosimilar to be approved in China, after Bio-Thera Solutions’s Qleti and Hisun Pharma’s HS016.